Nemesis Bioscience Closes Funding Round And Begins Preclinical Programmes
Nemesis Bioscience today announced the successful completion of its latest funding round, bringing total seed…read more
Nemesis Bioscience was founded in 2014 to address the global threat posed by increasing bacterial resistance to commonly used antibiotics.
Nemesis will commercialise inventions to make existing antibiotics effective once more by not only overcoming resistant bacterial infections but also by preventing them in susceptible patients.
Associated Fund UK Innovation & Science Seed Fund
Sector Medical / Biotechnology